PURPOSE: To determine a biweekly dose of oxaliplatin for combination with full-dose gemcitabine and concurrent radiation therapy (RT) in pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated pancreatic cancer received gemcitabine days 1, 8, and 15, and oxaliplatin days 1 and 15, repeated at 28-day intervals. RT (27 Gy in 1.8-Gy fractions) was administered during cycle 1. Dose escalation was guided using the time-to-event continuous reassessment method. Dose levels 1 to 4 included gemcitabine 1 g/m2 intravenously (IV) during 30 minutes and oxaliplatin 40, 55, 70, or 85 mg/m2 IV during 90 minutes, respectively; for dose levels 5 and 6, oxaliplatin dose remained 85 mg/m2 but infusion time for gemcitabine 1 g/m2 was increased to 65 or 100 minutes, respectively. The trial objective was to determine the dose level associated with dose-limiting toxicity (DLT) through cycle 2 in < or = 20% of patients. RESULTS: Forty-four patients were enrolled (median age, 64 years; 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastatic (n = 3) pancreatic cancer. Ten DLTs occurred in nine patients, including grade 4 platelets (n = 4), decline in performance status (n = 2), GI bleeding (n = 2), and GI toxicity (n = 2). The estimated probability of DLT for dose level 3 was .21 (90% posterior probability interval [PI], .12 to .33); for dose level 4, the estimated probability was .24 (90% PI, .14 to .36). CONCLUSION: The addition of oxaliplatin 85 mg/m2 days 1 and 15 to full-dose gemcitabine and radiation therapy was well tolerated. On the basis of these results, a multi-institutional neoadjuvant phase II study in resectable pancreatic cancer is planned.
PURPOSE: To determine a biweekly dose of oxaliplatin for combination with full-dose gemcitabine and concurrent radiation therapy (RT) in pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated pancreatic cancer received gemcitabine days 1, 8, and 15, and oxaliplatin days 1 and 15, repeated at 28-day intervals. RT (27 Gy in 1.8-Gy fractions) was administered during cycle 1. Dose escalation was guided using the time-to-event continuous reassessment method. Dose levels 1 to 4 included gemcitabine 1 g/m2 intravenously (IV) during 30 minutes and oxaliplatin 40, 55, 70, or 85 mg/m2 IV during 90 minutes, respectively; for dose levels 5 and 6, oxaliplatin dose remained 85 mg/m2 but infusion time for gemcitabine 1 g/m2 was increased to 65 or 100 minutes, respectively. The trial objective was to determine the dose level associated with dose-limiting toxicity (DLT) through cycle 2 in < or = 20% of patients. RESULTS: Forty-four patients were enrolled (median age, 64 years; 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastatic (n = 3) pancreatic cancer. Ten DLTs occurred in nine patients, including grade 4 platelets (n = 4), decline in performance status (n = 2), GI bleeding (n = 2), and GI toxicity (n = 2). The estimated probability of DLT for dose level 3 was .21 (90% posterior probability interval [PI], .12 to .33); for dose level 4, the estimated probability was .24 (90% PI, .14 to .36). CONCLUSION: The addition of oxaliplatin 85 mg/m2 days 1 and 15 to full-dose gemcitabine and radiation therapy was well tolerated. On the basis of these results, a multi-institutional neoadjuvant phase II study in resectable pancreatic cancer is planned.
Authors: Harvey J Mamon; Donna Niedzwiecki; Donna Hollis; Benjamin R Tan; Robert J Mayer; Joel E Tepper; Richard M Goldberg; A William Blackstock; Charles S Fuchs Journal: Cancer Date: 2010-12-23 Impact factor: 6.860
Authors: Laura Raftery; Joel E Tepper; Richard M Goldberg; A William Blackstock; Mebea Aklilu; Stephen A Bernard; Anastasia Ivanova; Janine M Davies; Bert H O'Neil Journal: Am J Clin Oncol Date: 2013-06 Impact factor: 2.339
Authors: Edward J Kim; Edgar Ben-Josef; Joseph M Herman; Tanios Bekaii-Saab; Laura A Dawson; Kent A Griffith; Isaac R Francis; Joel K Greenson; Diane M Simeone; Theodore S Lawrence; Daniel Laheru; Christopher L Wolfgang; Terence Williams; Mark Bloomston; Malcolm J Moore; Alice Wei; Mark M Zalupski Journal: Cancer Date: 2013-05-29 Impact factor: 6.860
Authors: R Wilkowski; S Boeck; S Ostermaier; R Sauer; M Herbst; R Fietkau; M Flentje; S Miethe; H D Boettcher; T Scholten; C J Bruns; H G Rau; A Hinke; V Heinemann Journal: Br J Cancer Date: 2009-11-10 Impact factor: 7.640
Authors: Ricky A Sharma; Ruth Plummer; Julie K Stock; Tessa A Greenhalgh; Ozlem Ataman; Stephen Kelly; Robert Clay; Richard A Adams; Richard D Baird; Lucinda Billingham; Sarah R Brown; Sean Buckland; Helen Bulbeck; Anthony J Chalmers; Glen Clack; Aaron N Cranston; Lars Damstrup; Roberta Ferraldeschi; Martin D Forster; Julian Golec; Russell M Hagan; Emma Hall; Axel-R Hanauske; Kevin J Harrington; Tom Haswell; Maria A Hawkins; Tim Illidge; Hazel Jones; Andrew S Kennedy; Fiona McDonald; Thorsten Melcher; James P B O'Connor; John R Pollard; Mark P Saunders; David Sebag-Montefiore; Melanie Smitt; John Staffurth; Ian J Stratford; Stephen R Wedge Journal: Nat Rev Clin Oncol Date: 2016-06-01 Impact factor: 66.675
Authors: K J Harrington; L J Billingham; T B Brunner; N G Burnet; C S Chan; P Hoskin; R I Mackay; T S Maughan; J Macdougall; W G McKenna; C M Nutting; A Oliver; R Plummer; I J Stratford; T Illidge Journal: Br J Cancer Date: 2011-07-19 Impact factor: 7.640